These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30684447)

  • 1. Mild-to-Moderate Ulcerative Colitis Guideline.
    Cross R; Ko CW; Singh S
    Gastroenterology; 2019 Feb; 156(3):768. PubMed ID: 30684447
    [No Abstract]   [Full Text] [Related]  

  • 2. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.
    Ko CW; Singh S; Feuerstein JD; Falck-Ytter C; Falck-Ytter Y; Cross RK;
    Gastroenterology; 2019 Feb; 156(3):748-764. PubMed ID: 30576644
    [No Abstract]   [Full Text] [Related]  

  • 3. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
    Singh S; Feuerstein JD; Binion DG; Tremaine WJ
    Gastroenterology; 2019 Feb; 156(3):769-808.e29. PubMed ID: 30576642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine.
    Guslandi M; Frego R; Viale E; Testoni PA
    Can J Gastroenterol; 2002 May; 16(5):293-6. PubMed ID: 12045777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild-to-Moderate Ulcerative Colitis (UC) Clinical Decision Support Tool.
    American Gastroenterological Association
    Gastroenterology; 2019 Feb; 156(3):765. PubMed ID: 30684448
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
    Olmstead J
    J Am Acad Nurse Pract; 2010 Nov; 22(11):586-92. PubMed ID: 21054632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic inflammatory bowel diseases. Proven and innovative in the treatment].
    MMW Fortschr Med; 2006 Jun; 148(24):43. PubMed ID: 16850809
    [No Abstract]   [Full Text] [Related]  

  • 9. "One more time" 5-ASA retrial after a glucocorticosteroid induced remission in moderate to severe ulcerative colitis: a prospective community practice experience.
    Lipka S; Katz S; Kaur N
    J Crohns Colitis; 2013 May; 7(4):342-3. PubMed ID: 22871515
    [No Abstract]   [Full Text] [Related]  

  • 10. [Second Korean Guideline for the Management of Ulcerative Colitis].
    Choi CH; Moon W; Kim YS; Kim ES; Lee BI; Jung Y; Yoon YS; Lee H; Park DI; Han DS;
    Korean J Gastroenterol; 2017 Jan; 69(1):1-28. PubMed ID: 28135789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: mesalazine in ulcerative colitis--is it time to revise treatment guidelines in the UK?
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():1. PubMed ID: 16939422
    [No Abstract]   [Full Text] [Related]  

  • 12. Once-daily mesalamine (Lialda) for ulcerative colitis.
    Med Lett Drugs Ther; 2007 Mar; 49(1257):25-6. PubMed ID: 17375030
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Take your medicine": nonadherence issues in patients with ulcerative colitis.
    Turnbough L; Wilson L
    Gastroenterol Nurs; 2007; 30(3):212-7; quiz 218-9. PubMed ID: 17568260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis.
    Aumais G; Lefebvre M; Massicotte J; Tremblay C; Kasbo J; Brunet JS; Cardinal C; Grace M; Spénard J
    Drugs R D; 2005; 6(1):41-6. PubMed ID: 15801866
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug development for ulcerative proctitis: current concepts.
    Caron B; Sandborn WJ; Schreiber S; Panaccione R; Danese S; Peyrin-Biroulet L
    Gut; 2021 Jul; 70(7):1203-1209. PubMed ID: 33789968
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis.
    Bitton A
    Semin Gastrointest Dis; 2001 Oct; 12(4):263-74. PubMed ID: 11726080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
    Kato S; Ishibashi A; Kani K; Yakabi K
    Digestion; 2018; 97(1):59-63. PubMed ID: 29393142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.